ATR — AptarGroup, Inc.

Summary of Aptar's Q1 2026 Earnings Call

1. Key Financial Results and Metrics:

• Sales Growth: Reported sales increased by 11%, while core sales (adjusted for currency and acquisitions) were flat year-over-year.
• Adjusted EBITDA: $189 million, up 3% from the prior year, with an adjusted EBITDA margin of 19.2%, down from 20.7% due to a less favorable product mix and operational challenges.
• Adjusted Earnings Per Share (EPS): $1.19, compared to $1.30 in the prior year, reflecting an 8% decline at comparable exchange rates.
• Free Cash Flow: More than doubled year-over-year to $53 million.
• Net Debt: $1.1 billion, with a leverage ratio of 1.43.

2. Strategic Updates and Business Highlights:

• Pharma Segment: Continued growth in areas such as GLP-1 biologics and systemic nasal drug delivery, though core sales decreased by 1% primarily due to a decline in emergency medicine products.
• Consumer Healthcare: Core sales increased by 4%, driven by eye care and nasal decongestant products.
• Beauty Segment: Core sales grew by 3%, supported by strong demand for prestige fragrance and color cosmetics.
• Closures Segment: Core sales were flat, impacted by lower resin pricing despite increased volumes.
• Litigation Update: Ongoing litigation with ARS Pharmaceuticals is progressing, with the court denying a motion to dismiss.

3. Forward Guidance and Outlook:

• Q2 2026 Guidance: Adjusted EPS expected to be in the range of $1.32 to $1.40. The effective tax rate is anticipated to be between 22.5% and 24.5%.
• Full Year 2026: Capital investments projected at $260 million to $280 million, with depreciation and amortization expenses expected between $310 million and $320 million.
• Growth Expectations: Anticipated solid growth across all segments in Q2, excluding the impact of emergency medicine destocking.

4. Bad News, Challenges, or Points of Concern:

• Emergency Medicine Decline: A significant decline in emergency medicine products is expected to impact sales by approximately $65 million for the full year, with a 3% negative impact on core sales in Q1.
• Margin Compression: Adjusted EBITDA margins are under pressure due to unfavorable product mix and operational challenges, particularly in beauty and closures.
• Operational Issues: Maintenance challenges and extreme weather conditions have affected production capabilities, particularly in the closures segment.
• Rising Input Costs: Increased costs for raw materials, transportation, and energy are anticipated, leading to margin compression as these costs are passed through to customers.

5. Notable Q&A Insights:

• Pharma Growth Expectations: Management expects solid growth in the prescription division, excluding emergency medicine, despite tough year-over-year comparisons.
• Supply Chain Management: The company is proactively managing supply chain risks and increasing safety stock to mitigate potential disruptions.
• GLP-1 Capacity: Investments have been made to ensure sufficient capacity for GLP-1 products, with no immediate need for additional capacity.
• Market Dynamics: The competitive landscape for emergency medicine products is evolving, with expectations of more stability in the future compared to the current volatility.
• Minority Investment Write-off: A small write-off related to a minority investment was noted, impacting margins but deemed not material overall.

Overall, Aptar's Q1 2026 results reflect a mixed operating environment with strong long-term growth prospects in key segments, albeit facing short-term challenges primarily related to emergency medicine destocking and operational issues.